Montreal / April 11, 2026 – NexPlasmaGen is immensely proud to announce that it is a finalist in the Medical Device category of the prestigious TieQuest 2026 competition and is making it to the Grand Final! TiEQuest 2026 (TiEQuest 2026 | TiE – Global Entrepreneurship Organization)...
We are proud to announce that NexPlasmaGen will be participating to the 6th edition of Invest-Tech, Québec’s must-attend event for innovative startups in AI, Deep Tech, and Med/Biotech! 📍 When & Where: 🗓 March 19, 2026 📍 Ax.c – Montréal (Place Victoria) 👉 https://luma.com/p65wv1wc 🚀 During the event, you’ll be...
February 20, 2026, New member of NexPlasmaGen's Business Advisory Committee Montreal / February 20, 2026 – NexPlasmaGen is immensely proud to announce that Mr. Howard Hechler has joined NexPlasmaGen's Business Advisory Committee! Howard Hechler has a 20-year track record of transforming innovative life sciences companies through strategic...
Montreal / August 21, 2025 - NexPlasmaGen is pleased to announce that Mr. Suman Mallick has joined NexPlasmaGen board! Suman Mallick is a Managing Director at Keystone National Group, where is the co-head of the Financial Assets practice and manages a portfolio of private credit investments....
Montreal / July 24, 2025 – NexPlasmaGen is proud to announce that it has secured a patent in South Korea to protect its Convertible Plasma Jet (CPJ) technology for breast cancer treatment. The patent application number in the Republic of Korea is No. 10-2022-7001947. This patent...
Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the clinical protocol for human safety trials initiated at CHUM with NexPlasmaGen medical technology for the treatment of breast cancer. The published article can...
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025 - The Centre hospitalier de l'Université de Montréal (CHUM) site has been activated to begin recruiting patients for safety trials with NexPlasmaGen's...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The Corporate LiveWire Innovation & Excellence Awards celebrate the success and achievements of leading professionals and companies who have stood out for being...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David Uffer, M.A, MBA joins NexPlasmaGen's Board of Directors. David is a 30+ yr seasoned executive having a career dedicated to the Medtech...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award. "GHP Magazine's Biotechnology Awards 2024” are designed to recognize and honor the most valuable contributors to the biotechnology industry, as well...